I agree with your assessment. At present the Brilacidin is not a part of the program. I do believe the program has potential future value. Should Brilacidin achieve good efficacy results in the FDA approved Phase II a Phase III will be needed. (EUA or not). The EU program provides a funding opportunity Innovation Pharmaceuticals should consider for Phase III.